SynteractHCR Expands With Four New Experts Added To Global Leadership Team
SynteractHCR , a full-service, international contract research organization (CRO), has appointed four new senior-level managers to its international leadership team. Miguel Fuentes joins as executive director, Service Delivery; Patrick F. Loebs, MSW, MPH, as senior regulatory affairs manager; Katharina Grote, as finance director, and Ewelina Mazur-Janik, MD, as medical monitor. The new executives draw on clinical research, operations, regulatory and finance experience from across the globe .
Based in Spain, Miguel Fuentes, executive director for service delivery, will provide leadership for development and implementation of tools and processes to expedite study start up, enrollment, conduct and closure, as well as global, regional and country improvements initiatives. He will report to Martina Kroener, managing director and vice president, European Operations. Fuentes draws on 20 years of clinical, regulatory and therapeutic experience in the areas of oncology, cardiovascular, infectious diseases, neuroscience, respiratory and inflammation. He leverages extensive experience in clinical operations, global site selection and management and project management from past experiences working at drug developers and CROs. Most recently, he was a global head, site selection for an international clinical research organization. He has a master of business administration degree in pharmaceutical and parapharmaceutical from CESIF Madrid, and a master of science degree in pharmacy, sanitary specialist from Universidad Complutense.
Patrick F. Loebs, MSW, MPH, joins SynteractHCR as a senior regulatory affairs manager working remotely and reporting to Dr. Martine Dehlinger-Kremer, vice president, Global Medical and Regulatory Affairs. As a primary contact for regulatory clients at SynteractHCR, Loebs will represent regulatory affairs on internal and external project teams, manage regulatory projects and ensure compliance with regulatory guidelines. Loebs draws on 30 years of experience in regulatory affairs, project management, medical writing and clinical operations across pharma, CRO and academic research organizations. He received master’s degrees in public health and social work from the University of North Carolina at Chapel Hill, in maternal child health and health administration, respectively.
Working from the Warsaw, Poland office, Dr. Ewelina Mazur-Janik joins as SynteractHCR’s oncology medical monitor. Mazur-Janik is a board-certified oncologist with extensive practice and pharmaceutical industry experience. She will also be reporting to Dr. Martine Dehlinger-Kremer. Mazur-Janik spent over nine years in clinical oncology, during which she treated patients with cancerous solid tumors, served as an investigator for clinical trials and participated in numerous congresses. She has also worked in hospitals in Poland, Los Angeles (Cedars-Sinai Medical Center) and Tel Aviv (Sheba Medical Center) and has laboratory research experience. Most recently she was a medical advisor at a global pharmaceutical company, responsible for medical affairs, supporting clinical development, safety, marketing, regulatory as well as patient relations. She graduated with a medical degree from the Medical University of Lodz, Poland. She is currently finalizing her PhD in history of medicine.
Katharina Grote is SynteractHCR’s new European finance director, working from the Munich office. In this role, Grote will report to Keith Kelson, chief financial officer, and be responsible for European accounting and finance functions, including overseeing the department and staff. Grote has over ten years in finance, tax consulting, accounting and auditing leadership experience at leading technology and professional services companies. She earned a degree in business administration, law and macroeconomics from the University of Bielefeld and holds qualified auditor and qualified tax advisor designations in Germany.
“At SynteractHCR, we realize our people are critical to our mission of collaborating with clients to create a better future for patients. For this reason, we look to the best and brightest and empower them to drive innovation and provide integrity in all that they do. Our latest new hires continue our commitment to leading the industry, as we further expand and grow our international presence to help pharmaceutical and biotech companies worldwide,” said Wendel Barr, CEO.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
Note to editors: Photographs available upon request.
Hilary McCarthy, 508-829-2543
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
IPSEN21.9.2018 07:32 | pressemeddelelse
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)
CA-QUANERGY-SYSTEMS21.9.2018 07:02 | pressemeddelelse
Quanergy Selected as Exclusive LiDAR Partner for VRCO
GLOBAL-RAYTUR21.9.2018 05:10 | pressemeddelelse
Overseas Roadshow for the IAPH Guangzhou 2019 World Ports Conference Was Held in London
MINDOL-HOLDINGS21.9.2018 03:02 | pressemeddelelse
AbuDhabi Dubai STOB Series 22 Investment Enters into Favorable Tender Offer Agreement with MINDOL HOLDINGS
AFTON-CHEMICAL20.9.2018 22:32 | pressemeddelelse
Afton Chemical’s S$380 Million Phase II Expansion of Its Jurong Island Plant is Now Complete
NY-IFF20.9.2018 22:17 | pressemeddelelse
IFF Announces Pricing of €1,100,000,000 Senior Notes Offering
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum